Prior studies have indicated that high baseline BAP and TRACP-5b levels are risk factors for hypocalcemia in patients undergoing hemodialysis based on the hypothesis that high bone turnover is associated with enhanced denosumab efficacy [16–18]. This evidence concerns the gene ACP5 and Hypocalcemia.